Outlook Therapeutics stockholders approve authorized share increase and reverse split

Outlook Therapeutics, Inc.

Authorized common stock increased from 260M to 600M shares via Certificate of Amendment filed July 16, 2026.
Reverse stock split approved at ratio 1:10 to 1:50, with exact ratio to be set by board of directors.
Stockholders approved issuance of shares underlying warrants from April 2026 private placement (up to 16.1M shares) and placement agent warrants.
Special meeting quorum was 51.5% (62.3M of 120.9M outstanding shares present or represented).
Proposal 2 (authorized share increase) passed with 24.4M for, 8.7M against; Proposal 3 (reverse split) passed with 44.3M for, 17.8M against.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.